International review of neurobiology最新文献_第9页

Adenosine A_2A signals and dystonia. 腺苷A2A信号与肌张力障碍。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-07-27 DOI: 10.1016/bs.irn.2023.06.001

Makio Takahashi

引用次数: 0

Susac syndrome can be diagnosed by examination and cured by comprehensive therapy. Susac综合征可通过检查诊断，综合治疗可治愈。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-06-23 DOI: 10.1016/bs.irn.2023.03.004

Feifei Jiang, Zhiming Ma, Zhizhi Chen, Ming Yang, Hongyun Huang, Lin Chen, Chao He

引用次数: 0

How and why the adenosine A_2A receptor became a target for Parkinson's disease therapy. 腺苷A2A受体如何以及为什么成为帕金森病治疗的靶点。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-05-14 DOI: 10.1016/bs.irn.2023.04.005

Peter Jenner, Tomoyuki Kanda, Akihisa Mori

{"title":"How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.","authors":"Peter Jenner, Tomoyuki Kanda, Akihisa Mori","doi":"10.1016/bs.irn.2023.04.005","DOIUrl":"https://doi.org/10.1016/bs.irn.2023.04.005","url":null,"abstract":"Dopaminergic therapy for Parkinson's disease has revolutionised the treatment of the motor symptoms of the illness. However, it does not alleviate all components of the motor deficits and has only limited effects on non-motor symptoms. For this reason, alternative non-dopaminergic approaches to treatment have been sought and the adenosine A2A receptor provided a novel target for symptomatic therapy both within the basal ganglia and elsewhere in the brain. Despite an impressive preclinical profile that would indicate a clear role for adenosine A2A antagonists in the treatment of Parkinson's disease, the road to clinical use has been long and full of difficulties. Some aspects of the drugs preclinical profile have not translated into clinical effectiveness and not all the clinical studies undertaken have had a positive outcome. The reasons for this will be explored and suggestions made for the further development of this drug class in the treatment of Parkinson's disease. However, one adenosine A2A antagonist, namely istradefylline has been introduced successfully for the treatment of late-stage Parkinson's disease in two major areas of the world and has become a commercial success through offering the first non-dopaminergic approach to the treatment of unmet need to be introduced in several decades.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"170 ","pages":"73-104"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies. 鼻-脑给药治疗中枢神经系统疾病：新进展和策略。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-06-21 DOI: 10.1016/bs.irn.2023.05.014

Li Du, Lin Chen, Fangfang Liu, Wenya Wang, Hongyun Huang

引用次数: 0

Adenosine A_2A receptor and glia. 腺苷A2A受体与胶质细胞。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-09-07 DOI: 10.1016/bs.irn.2023.08.002

Zhihua Gao

引用次数: 1

Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease. tau和神经元一氧化氮合酶抗体的纳米线递送与脑溶素一起减轻帕金森病中创伤性脑损伤引起的脑病理恶化。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-09-15 DOI: 10.1016/bs.irn.2023.07.001

Asya Ozkizilcik, Aruna Sharma, Lianyuan Feng, Dafin F Muresanu, Z Ryan Tian, José Vicente Lafuente, Anca D Buzoianu, Ala Nozari, Lars Wiklund, Hari Shanker Sharma

{"title":"Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease.","authors":"Asya Ozkizilcik, Aruna Sharma, Lianyuan Feng, Dafin F Muresanu, Z Ryan Tian, José Vicente Lafuente, Anca D Buzoianu, Ala Nozari, Lars Wiklund, Hari Shanker Sharma","doi":"10.1016/bs.irn.2023.07.001","DOIUrl":"10.1016/bs.irn.2023.07.001","url":null,"abstract":"Concussive head injury (CHI) is one of the major risk factors for developing Parkinson's disease in later life of military personnel affecting lifetime functional and cognitive disturbances. Till date no suitable therapies are available to attenuate CHI or PD induced brain pathology. Thus, further exploration of novel therapeutic agents are highly warranted using nanomedicine in enhancing the quality of life of veterans or service members of US military. Since PD or CHI induces oxidative stress and perturbs neurotrophic factors regulation associated with phosphorylated tau (p-tau) deposition, a possibility exists that nanodelivery of agents that could enhance neurotrophic factors balance and attenuate oxidative stress could be neuroprotective in nature. In this review, nanowired delivery of cerebrolysin-a balanced composition of several neurotrophic factors and active peptide fragments together with monoclonal antibodies to neuronal nitric oxide synthase (nNOS) with p-tau antibodies was examined in PD following CHI in model experiments. Our results suggest that combined administration of nanowired antibodies to nNOS and p-tau together with cerebrolysin significantly attenuated CHI induced exacerbation of PD brain pathology. This combined treatment also has beneficial effects in CHI or PD alone, not reported earlier.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"171 ","pages":"83-121"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glial-mediated dysregulation of neurodevelopment in Fragile X Syndrome. 脆性X综合征中神经发育的神经胶质介导失调。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-09-16 DOI: 10.1016/bs.irn.2023.08.005

M Napier, K Reynolds, A L Scott

引用次数: 0

Nicotine neurotoxicity exacerbation following engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron. 工程Ag和Cu（50-60nm）纳米粒子中毒后尼古丁神经毒性加重。抗氧化化合物H-290/51与5-羟色胺5-HT3受体拮抗剂昂丹司琼的纳米线递送的神经保护作用。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-09-26 DOI: 10.1016/bs.irn.2023.07.002

Z Ryan Tian, Aruna Sharma, Dafin F Muresanu, Suraj Sharma, Lianyuan Feng, Zhiqiang Zhang, Cong Li, Anca D Buzoianu, José Vicente Lafuente, Ala Nozari, Per-Ove Sjöqvisst, Lars Wiklund, Hari Shanker Sharma

{"title":"Nicotine neurotoxicity exacerbation following engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron.","authors":"Z Ryan Tian, Aruna Sharma, Dafin F Muresanu, Suraj Sharma, Lianyuan Feng, Zhiqiang Zhang, Cong Li, Anca D Buzoianu, José Vicente Lafuente, Ala Nozari, Per-Ove Sjöqvisst, Lars Wiklund, Hari Shanker Sharma","doi":"10.1016/bs.irn.2023.07.002","DOIUrl":"10.1016/bs.irn.2023.07.002","url":null,"abstract":"Nicotine abuse is frequent worldwide leading to about 8 millions people die every year due to tobacco related diseases. Military personnel often use nicotine smoking that is about 12.8% higher than civilian populations. Nicotine smoking triggers oxidative stress and are linked to several neurodegenerative diseases such as Alzheimer's disease. Nicotine neurotoxicity induces significant depression and oxidative stress in the brain leading to neurovascular damages and brain pathology. Thus, details of nicotine neurotoxicity and factors influencing them require additional investigations. In this review, effects of engineered nanoparticles from metals Ag and Cu (50-60 nm) on nicotine neurotoxicity are discussed with regard to nicotine smoking. Military personnel often work in the environment where chances of nanoparticles exposure are quite common. In our earlier studies, we have shown that nanoparticles alone induces breakdown of the blood-brain barrier (BBB) and exacerbates brain pathology in animal models. In present investigation, nicotine exposure in with Ag or Cu nanoparticles intoxicated group exacerbated BBB breakdown, induce oxidative stress and aggravate brain pathology. Treatment with nanowired H-290/51 a potent chain-breaking antioxidant together with nanowired ondansetron, a potent 5-HT3 receptor antagonist significantly reduced oxidative stress, BBB breakdown and brain pathology in nicotine exposure associated with Ag or Cu nanoparticles intoxication. The functional significance of this findings and possible mechanisms of nicotine neurotoxicity are discussed based on current literature.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"172 ","pages":"189-233"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention. 自体造血干细胞染色质的基因组平衡技术，用于文明、延长预期寿命和预防人类猝死的致命免疫介导疾病的基因治疗。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-09-26 DOI: 10.1016/bs.irn.2023.07.005

A S Bryukhovetskiy, L Yu Grivtsova, S S Bogachev, A A Ustyugov, V O Nebogatikov, M A Shurdov

{"title":"Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention.","authors":"A S Bryukhovetskiy, L Yu Grivtsova, S S Bogachev, A A Ustyugov, V O Nebogatikov, M A Shurdov","doi":"10.1016/bs.irn.2023.07.005","DOIUrl":"10.1016/bs.irn.2023.07.005","url":null,"abstract":"A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNAnmr) has been developed and implemented in the clinic to change (to \"correct\") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of civilization. A fundamentally new biotechnological approach has been applied to the delivery of genetic material into eukaryotic stem and progenitor cells by establishing an artificial \"recombinogenic situation\" in them to induce homologous recombination (equivalent replacement) of mutant DNA regions with healthy hDNAnmr. In experimental preclinical trials, the effectiveness of genomic balancing technology has been proven to reduce the risk of sudden death in old animals and to increase the lifespan of outbred mice by 30% and Wistar rats by 57%. The improvement in their quality of life, compared with the control, is explained by an increase in the telomeric regions of the HSCs and HPCs chromosomes by 1.5-2 times. The potential of the technology to slow down the hereditary neurodegenerative diseases on the model of amyotrophic lateral sclerosis is shown. The effectiveness of this technology in clinical practice is presented on the example of a terminal patient with stage 4 neuroendocrine cancer. This technology used in the treatment of a number of oncological, neurodegenerative, autoimmune and hereditary diseases with clonal hematopoiesis is able to arrest the progression of the disease, prevent its recurrence, prolong the active life of a person, increase the average life expectancy and prevent sudden death.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"172 ","pages":"237-284"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How dendritic spines shape is determined by MMP-9 activity in FXS. FXS中MMP-9活性如何决定树突棘的形状。

International review of neurobiology Pub Date : 2023-01-01 Epub Date: 2023-11-07 DOI: 10.1016/bs.irn.2023.10.001

Magdalena Dziembowska

引用次数: 0